GCT-007
Glioblastoma Multiforme (GBM)
Key Facts
About Global Cancer Technology
Global Cancer Technology is a private, pre-revenue biotech targeting high-unmet-need cancers, particularly glioblastoma multiforme (GBM). Its core technology involves small molecule inhibitors, notably GCT-007, which uniquely targets both PI3K and mTOR pathways to overcome resistance and modulate the tumor microenvironment. The company is in preclinical development, with ambitious goals to initiate Phase 1/2 trials by 2027, and is currently raising capital from accredited investors.
View full company profileAbout Global Cancer Technology
Global Cancer Technology is a private, pre-revenue biotech targeting high-unmet-need cancers, particularly glioblastoma multiforme (GBM). Its core technology involves small molecule inhibitors, notably GCT-007, which uniquely targets both PI3K and mTOR pathways to overcome resistance and modulate the tumor microenvironment. The company is in preclinical development, with ambitious goals to initiate Phase 1/2 trials by 2027, and is currently raising capital from accredited investors.
View full company profileOther Glioblastoma Multiforme (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| TLR-AD1 | NovAccess Global | Pre-IND |
| Tinostamustine | Imbrium Therapeutics | Phase 2 |
| Dendritic Cell Vaccine | Mill Creek Life Sciences | Pre-clinical |
| CYNK-GDT | Celularity | Preclinical |